Long-Acting Methods of Contraception by Peterson, Herbert B. & Curtis, Kathryn M.
 
























 feature begins with a case vignette highlighting a common clinical problem. 
Evidence supporting various strategies is then presented, followed by a review of formal guidelines, 
when they exist. The article ends with the authors’ clinical recommendations.
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A healthy, multiparous 23-year-old woman requests advice about contraception. Her
last child was conceived while she was using oral contraceptives, which she took ir-
regularly. She wants no more children and desires a highly effective and long-acting
method of contraception. She is sexually active in a monogamous relationship and
had been treated for gonococcal cervicitis at the age of 16 years. She has normal menses.
Findings on pelvic examination are normal. What contraceptive methods are appro-
priate for her?
 
Modern contraceptives have enabled countless women and couples to plan their preg-
nancies; nevertheless, approximately 80 million unintended pregnancies occur each
year worldwide. In the United States, nearly half (48 percent) of women aged 15 to 44




 Although many of these
unplanned pregnancies occur among women not using contraception, slightly more





these pregnancies result from incorrect or inconsistent use of contraception, but some




Contraceptive methods vary in their effectiveness and in the determinants of effec-
tive use. For example, oral contraceptives are highly effective when taken properly but




 Injectable methods of contraception offer an alter-
native to daily pill taking but require reinjection at regular intervals. Other highly effec-
tive methods that do not require frequent effort are available, and these long-acting
methods are the focus of this review. Two of these methods — intrauterine devices
(IUDs) and progestin implants — can be used by women regardless of whether they
are spacing their pregnancies or have completed childbearing. Two other methods —
tubal sterilization for women and vasectomy for men — are intended only for those






Worldwide, IUDs are the most popular nonpermanent method of contraception, used
by nearly 160 million women. However, only 2 percent of women using contraception




 Two IUDs are currently available in the
United States: the copper T380A (ParaGard, FEI Women’s Health), which has a copper




, and the levonorgestrel-releasing intrauterine
system (Mirena, Berlex Laboratories), which releases levonorgestrel at a rate of approx-
imately 20 µg per day.
IUDs are highly effective in preventing pregnancy (Table 1). A recent analysis found
the clinical problem
strategies and evidence
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that the copper T380A and the levonorgestrel-
releasing intrauterine system were the most cost-
effective, nonpermanent methods of contraception





 Multiple mechanisms of action prob-





precise contribution of each mechanism is unclear,
and the extent to which prevention of implantation




 There is evidence,
however, that the copper T380A works primarily by
prevention of fertilization through mechanisms




The likelihood of expulsion of an IUD can be re-
duced with proper insertion technique. Reported




 In a large, multi-
country trial with seven years of follow-up, cumu-
lative discontinuation rates for expulsion with the
copper T380A and the levonorgestrel-releasing in-
trauterine system were 1.8 and 2.9, respectively, per




 Expulsion is believed to be more








In the uncommon event of pregnancy while us-
ing an IUD, the risk of complications — including
ectopic gestation, spontaneous abortion, and pre-




 The absolute risk of
ectopic pregnancy, however, is low (approximately
1 per 1000 person-years) and is less than half the





pregnancy is intrauterine, the Food and Drug Ad-
ministration (FDA) recommends that the device be
removed, if removal can be accomplished without
an invasive procedure. Whether in utero exposure to
levonorgestrel increases the risk of fetal abnormal-
ities is unknown.
The main side effects of IUDs are menstrual ab-
normalities. Heavy bleeding, intermenstrual spot-
ting, and menstrual pain are common among the
users of copper IUDs; amenorrhea is more common
among users of the levonorgestrel-releasing intra-
uterine system (Table 1). In a report from Finland,
women who were provided information about the
possibility of amenorrhea were significantly more
likely to be satisfied with the levonorgestrel-releas-
ing intrauterine system than were women who had




The popularity of IUDs declined markedly in the




 after reports of se-
rious pelvic infections with use of the Dalkon Shield,
which was marketed in the early 1970s. Studies in
the late 1980s and 1990s, however, provided strong
and reassuring evidence that women at low risk for
sexually transmitted infections were at low risk for





bined data from 13 World Health Organization
(WHO) studies that excluded women with sexually
transmitted infections during the previous six
months and those with previous pelvic inflamma-
tory disease and involved more than 50,000 per-
son-years of follow-up, found that the risk of pelvic
inflammatory disease was 1.6 cases per 1000 per-





 Randomized trials of wom-
en at low risk for sexually transmitted infections
have found no benefit of antibiotic prophylaxis in
reducing this insertion-associated risk; rates of
pelvic infections were comparably low with pro-
phylaxis (0.1 to 1.7 percent) and without prophy-




IUDs appear to cause little, if any, increase in the
risk of infertility among women who are at low risk





three case–control studies have found no associa-
tion between the use of IUDs and infertility among





The risk of uterine perforation is low when





large cohort study in New Zealand found a rate of







Several subdermal implants provide highly effective,
long-acting contraception. These implants consist
of polymer capsules or rods that deliver a proges-
tin. Four progestins have been used in implants to
date: levonorgestrel, etonogestrel, Nestorone, and
nomegestrol acetate. None of these implants are
currently marketed in the United States, although
two levonorgestrel implants — a set of six silicone
elastomer capsules (Norplant) and a set of two sili-
cone elastomer rods (Jadelle) — have been approved
by the FDA. Implanon consists of a single rod that
contains the progestin etonogestrel; it has been ap-
proved for three years of use in the European Union,
Canada, and Indonesia and is currently under re-
view by the FDA.
Progestin implants are highly effective (Table 1),
with recent multinational studies reporting five-year
cumulative pregnancy rates of 1.5 percent or less





studies are lacking, Implanon appears to be at least
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mechanisms of action for progestin-only implants





all progestin-only implants have at least some ef-
fect on ovarian function, Implanon was specifically
designed to prevent ovulation and is highly effec-









 found no increase in the rates of adverse out-
comes, including pelvic inflammatory disease, loss
of bone mineral density, anemia, thrombocytope-
nia, and death in women who used implants, as
compared with nonusers. Although data were in-
sufficient to draw conclusions regarding cardiovas-
cular events (stroke, myocardial infarction, throm-
boembolism) and cancers, absolute rates for these
outcomes were very low (less than 1 per 10,000
person-years).
The main side effect of progestin-only implants,





 Rates and types of menstru-





Approximately 180 million women worldwide have
undergone tubal sterilization. In 2002 in the Unit-
ed States, 28 percent of women between the ages of





 Approximately half of tubal
sterilizations in the United States are performed
post partum with the use of partial salpingectomy,
either by minilaparotomy after vaginal delivery or
concurrent with cesarean delivery. Most other pro-
cedures are performed by laparoscopy at a time un-
related to delivery with the use of either coagulation
or application of clips or bands. In 2002, the FDA
approved a new tubal occlusion device (Essure,
Conceptus) that is placed with use of hysteroscopy.
Tubal sterilization is highly effective. The cumu-
lative probability of pregnancy at 10 years after the
procedure ranges from 1.8 to 54.3 per 1000 proce-





 (although data are insuffi-
cient to identify any one method as clearly superior).
When pregnancies occur after tubal sterilization, a
high proportion are ectopic (15 to 65 percent, de-




 although the absolute
risk of ectopic pregnancy is very low after this pro-
cedure. An analysis of data from the U.S. Collabora-
tive Review of Sterilization, which included 10,685
women who had undergone sterilization at medical
centers in nine U.S. cities, found that the 10-year
cumulative probability of ectopic pregnancy for all
methods of tubal sterilization examined was 7.3
per 1000 procedures (range, 1.5 to 17.1 per 1000,




 Overall, the propor-
tion of pregnancies that were ectopic was three
times as high in years 4 to 10 after sterilization (61
percent) as it was in years 1 to 3 (20 percent).
Deaths associated with tubal sterilization in the





 and serious morbidity is
uncommon. According to the U.S. Collaborative
Review of Sterilization, unintended major surgery
occurred in 0.9 percent of 9475 laparoscopic steril-
izations, and rehospitalization occurred in 0.6 per-





 Risk factors for complications included
diabetes, general anesthesia, previous abdominal




Although some previous reports described a
post-sterilization syndrome involving menstrual ab-
normalities, more recent data indicate that a syn-
drome of menstrual abnormalities is no more like-
ly to develop in women undergoing sterilization





 Although indications for hysterectomy
should be the same for women who have undergone





who had undergone sterilization were more likely
to undergo subsequent hysterectomy, according










Most women report no change in sexual
interest or pleasure after tubal sterilization; of those




Sterilization is intended to be permanent and
should be performed only in people who are fully
informed and choose to prevent pregnancy perma-
nently. Surgical procedures to reverse tubal steriliza-
tion and vasectomy — along with the predominant
alternative, in vitro fertilization — are expensive and
often unsuccessful. The likelihood of pregnancy af-
ter surgical reversal of either tubal sterilization or
vasectomy depends on several factors, including the
method of tubal or vas occlusion and the age of the
woman. Although most people remain satisfied
with their decision to undergo sterilization, feelings
of regret after the procedure are not rare. Women
who are sterilized at a young age are at greater risk
for later regret, regardless of the number of children





the U.S. Collaborative Review of Sterilization, the
14-year cumulative probability of requesting infor-
mation about reversal was 14.3 percent, but the
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probability rose to 40.4 percent among women
who were between the ages of 18 and 24 years at




 The cumulative probabil-
ity of expressing regret within five years was similar
for women who underwent tubal sterilization (7.0
percent) and for women whose husbands under-






Worldwide, almost 43 million men have undergone
sterilization. In 2002, 9 percent of U.S. women of





Vasectomy is generally per-
formed on an outpatient basis under local anesthe-
sia, either by the no-scalpel technique (performed
through a small puncture) or by incision, and with
the use of a variety of methods of occlusion. Vasec-




 with an estimated
pregnancy rate for all methods combined of 0.15





term effectiveness of vasectomy is less well studied
than that of tubal sterilization; the long-term effec-
tiveness of vasectomy, like that of tubal steriliza-




 (although data are
insufficient to identify any one method as clearly
superior). It is recommended that the effectiveness
of vasectomy be confirmed by semen analysis at




Surgical complications from vasectomy are in-
frequent and usually minor, and include hematoma
formation, wound infection, acute epididymitis, and
sperm granulomas (with each complication report-





complications and deaths are rare. Chronic testicu-
lar pain is a possible late complication. Numerous
observational studies have provided reassurance
that vasectomy does not increase the risk of pros-





It is unclear whether infections of the lower genital
tract that occur after insertion of IUDs are more
likely to ascend into the upper genital tract than if
the devices were not present. Thus, whether IUDs
pose an increased risk to women in whom gono-
coccal or chlamydial cervicitis develops or, like oth-
er long-acting contraceptive methods, merely do





Several case–control studies have found a re-
duced risk of endometrial cancer associated with





it is unclear whether this association is causal. Sup-
pressive effects of the levonorgestrel intrauterine





tribute to a reduction in endometrial cancer risk,
but this is uncertain.
It is controversial whether there is a post-vasec-
tomy pain syndrome, variably defined as chronic





 Surveys of men who have undergone vasecto-















 These surveys had low response
rates, lack comparison groups, and may not be gen-
eralizable to the general population. The Health Sta-
tus of American Men study, a retrospective cohort
study in which 10,590 men with vasectomy were
matched with neighborhood controls, reported an
incidence of epididymitis–orchitis occurring more
than 12 months after vasectomy of 24.7 per 10,000
person-years, as compared with 13.6 per 10,000
person-years among men without vasectomy; these
rates were significantly different but were not ad-





es of pain after vasectomy include epididymal con-





Limited data from case series
suggest that some men with chronic pain after va-
sectomy who do not respond to conservative therapy




 or other surgi-
cal management.
The WHO has developed recommendations for
the use of IUDs and progestin implants (Table 1)





can College of Obstetricians and Gynecologists has










Women who desire a highly effective, long-acting
method of contraception have several options. Most
of these women, like the person in the vignette, are
appropriate candidates for an IUD or progestin im-
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would not contraindicate the use of an IUD in a
woman whose risk for current and future infections
is low. However, a woman who currently has a cervi-
cal gonococcal or chlamydial infection should not
have an IUD inserted. The most troubling side ef-
fects of IUDs and progestin implants are menstrual
abnormalities, and women should be informed
about these effects; for some women, these prob-
lems are acceptable trade-offs for highly effective,
long-acting contraception. For couples choosing
permanent contraception, both tubal sterilization
and vasectomy have low surgical risks and are high-
ly effective; vasectomy, however, is safer and, in gen-
eral, appears to be at least as effective. Only women
and men who make a fully informed and well-con-
sidered decision to prevent pregnancy permanently
are appropriate candidates for sterilization. Wheth-
er the woman in this vignette meets these criteria
could be determined only after careful counseling.
Although women should not be denied tubal steril-
ization because of young age alone, many such
women are well served by using another long-acting
method, at least for several years.
 
The findings and conclusions in this report are those of the au-
thors and do not necessarily represent the views of the Centers for
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Table 2. Use of IUDs and Sterilization.*
Contraceptive Method Recommendations
 
Copper IUD and levonorgestrel-releasing
intrauterine system
Nulligravid and multiparous women at low risk for sexually transmitted dis-
eases who desire long-term, reversible contraception are good candidates.
Tubal sterilization and vasectomy Patients considering sterilization should be advised that the procedure is in-
tended to be permanent; that it will not provide protection against sexu-
ally transmitted diseases (including human immunodeficiency virus in-
fection); that the morbidity and mortality associated with tubal 
sterilization (though low) are higher than for vasectomy; that the effec-
tiveness of the two methods is similar; and that the effectiveness of tubal 
sterilization is higher than that of short-term reversible methods and 
similar to that of the IUD.
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